Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism
Advanced Science · 2026-04 · 13 (19)
DOI: 10.1002/advs.202518468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.01.2026. Verfasst von Yeneng Dai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nanoparticles, Immunotherapy, Oligopeptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Science and Technology Development Fund of Macau.
Abstract (Originalsprache)
Despite the promise of combining chemotherapy and immunotherapy for triple‐negative breast cancer (TNBC), challenges remain due to targeting deficiencies and accelerated T cell exhaustion within the immunosuppressive tumor microenvironment (TME). To address these limitations, we developed a drug‐encapsulated lipid nanoparticle (LNP) system to reprogram tumor metabolism and reverse acquired immune tolerance. This LNP encapsulates the cytotoxic agent monomethyl auristatin E (MA) and the immunomodulator metformin (Met), followed by conjugated to a human receptor tyrosine kinase‐like orphan receptor 1 antibody (ROR1 Ab) via an acid‐labile linker. ROR1 Ab‐mediated active targeting enables precise tumor localization through NIR‐II fluorescence imaging, and enhances chemotherapeutic efficacy while minimizing off‐target toxicity. Critically, metformin incorporated into the lipid formulation inhibits both membrane and cytoplasmic PD‐L1 expression and reduces TGF‐β1 levels by suppressing mitochondrial oxidative phosphorylation (OXPHOS), thereby restoring T lymphocyte activity and amplifying the immune response. This work demonstrates a novel approach to enhance TNBC treatment through targeted modulation of tumor metabolism and immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
- MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, China.
- Department of Paediatrics, the Chinese University of Hong Kong, Hong Kong, China.
- School of Life Sciences, Central South University, Changsha, China.
ORCID-Profile: Qi Zhao
Förderung
- Natural Science Foundation of Guangdong Province
- Science and Technology Development Fund of Macau
Zitieren
APA
Dai, Y., Wang, J., Liu, Y., Jiao, G., Gu, Y., Liu, Y., Fu, S., Fan, X., Li, J., Guo, Z., Leung, K. T., Zhu, L., & Zhao, Q. (2026). Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism. Advanced Science, 13(19). https://doi.org/10.1002/advs.202518468
Vancouver
Dai Y, Wang J, Liu Y, Jiao G, Gu Y, Liu Y, et al. Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism. Advanced Science. 2026;13(19). doi:10.1002/advs.202518468
BibTeX
@article{Dai2026,
author = {Dai, Yeneng and Wang, Jiaqi and Liu, Yu and Jiao, Guanda and Gu, Yuheng and Liu, Yang and Fu, Shengyu and Fan, Xing and Li, Jialin and Guo, Ziang and Leung, Kam Tong and Zhu, Lipeng and Zhao, Qi},
title = {Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {19},
doi = {10.1002/advs.202518468}
}
EUVIMED